1）Bangham AD, Horne RW. Negative staining of
phospholipids and their structural modification by
surface-active agents as observed in the electron
microscope. J Mol Biol. 1964;8:660-668. doi:
10.1016/s0022-2836（64）80115-7.
2） Al-Jamal WT, Kostarelos K. Liposomes: from
a clinically established drug delivery system to a
nanoparticle platform for theranostic nanomedicine.
Acc Chem Res. 2011;44:1094-1104. doi: 10.1021/
ar200105p.
3） Goyal P, Goyal K, Vijaya Kumar SG, Singh
A, Katare OP, Mishra DN. Liposomal drug delivery systems--clinical applications. Acta Pharm.
2005;55:1-25.
4） Torchilin VP. Recent advances with liposomes
as pharmaceutical carriers. Nat Rev Drug Discov.
2005;4:145-160. doi: 10.1038/nrd1632.
5）Allen C, Dos Santos N, Gallagher R, et al. Controlling the physical behavior and biological performance of liposome formulations through use of
surface grafted poly（ethylene glycol）
. Biosci Rep.
2002;22:225-250. doi: 10.1023/a:1020186505848.
6） Caliceti P, Veronese FM. Pharmacokinetic and
biodistribution properties of poly （ethylene glycol）-protein conjugates. Adv Drug Deliv Rev.
59
2003;55:1261-1277. doi: 10.1016/s0169-409x
（03）
00108-x.
7） Kulkarni JA, Cullis PR, van der Meel R. Lipid Nanoparticles Enabling Gene Therapies: From
Concepts to Clinical Utility. Nucleic Acid Ther.
2018;28:146-157. doi: 10.1089/nat.2018.0721.
8） Schmidt A, Morales-Prieto DM, Pastuschek J,
Fröhlich K, Markert UR. Only humans have human placentas: molecular differences between mice
and humans. J Reprod Immunol. 2015;108:65-71.
doi: 10.1016/j.jri.2015.03.001.
9） H a i g D . R e t r o v i r u s e s a n d t h e p l a c e n t a .
Curr Biol. 2 0 1 2;2 2:R6 0 9-6 1 3. doi: 1 0.1 0 1 6/
j.cub.2012.06.002.
10） Gaspar DP, Gaspar MM, Eleutério CV, et al.
Microencapsulated Solid Lipid Nanoparticles as a
Hybrid Platform for Pulmonary Antibiotic Delivery.
Mol Pharm. 2017;14:2977-2990. doi: 10.1021/acs.
molpharmaceut.7b00169.
11）Swingle KL, Billingsley MM, Bose SK, et al.
Amniotic fluid stabilized lipid nanoparticles for
in utero intra-amniotic mRNA delivery. J Control Release. 2022;341:616-633. doi: 10.1016/
j.jconrel.2021.10.031.
12）Landon MB, Galan HL, Jauniaux ERM, et al.
Gabbe’s obstetrics : normal and problem pregnancies. 8th ed. Philadelphia, PA: Elsevier; 2021.
13） Dubil EA, Magann EF. Amniotic fluid as a
vital sign for fetal wellbeing. Australas J Ultrasound Med. 2013;16:62-70. doi: 10.1002/j.22050140.2013.tb00167.x.
14） Renfree MB, Hensleigh HC, McLaren A. Developmental changes in the composition and
amount of mouse fetal fluids. J Embryol Exp
Morphol. 1975;33:435-446.
15） Zhi LJ, Sun AL, Tang D. In situ amplified
photothermal immunoassay for neuron-specific
enolase with enhanced sensitivity using Prussian blue nanoparticle-loaded liposomes. Analyst.
2020;145:4164-4172. doi: 10.1039/d0an00417k.
16）van Elk M, van den Dikkenberg JB, Storm G,
Hennink WE, Vermonden T, Heger M. Preclinical
evaluation of thermosensitive poly（N-（2-hydroxypropyl） methacrylamide mono/dilactate）-grafted liposomes for cancer thermochemotherapy.
Int J Pharm. 2018;550:190-199. doi: 10.1016/
j.ijpharm.2018.08.027.
60
OGAWA et al.
17）Al-Jamal WT, Al-Jamal KT, Tian B, Cakebread
A, Halket JM, Kostarelos K. Tumor targeting
of functionalized quantum dot-liposome hybrids by intravenous administration. Mol Pharm.
2009;6:520-530. doi: 10.1021/mp800187d.
18）Zhang QY, Ho PY, Tu MJ, et al. Lipidation of
polyethylenimine-based polyplex increases serum
stability of bioengineered RNAi agents and offers
more consistent tumoral gene knockdown in vivo.
Int J Pharm. 2018;547:537-544. doi: 10.1016/
j.ijpharm.2018.06.026.
19）Cheung CY, Brace RA. Amniotic fluid volume
and composition in mouse pregnancy. J Soc Gynecol Investig. 2005;12:558-562. doi: 10.1016/
j.jsgi.2005.08.008.
20）Tong XL, Wang L, Gao TB, Qin YG, Qi YQ,
Xu YP. Potential function of amniotic fluid in fetal development---novel insights by comparing the
composition of human amniotic fluid with umbilical cord and maternal serum at mid and late gestation. J Chin Med Assoc. 2009;72:368-373. doi:
10.1016/S1726-4901（09）70389-2.
21） Jørgensen MC, Ahnfelt-Rønne J, Hald J,
Madsen OD, Serup P, Hecksher-Sørensen J. An
illustrated review of early pancreas development
in the mouse. Endocr Rev. 2007;28:685-705. doi:
10.1210/er.2007-0016.
22） Thoby-Brisson M, Trinh JB, Champagnat J,
Fortin G. Emergence of the pre-Bötzinger respi-
ratory rhythm generator in the mouse embryo.
J Neurosci. 2005;25:4307-4318. doi: 10.1523/
JNEUROSCI.0551-05.2005.
23）Alapati D, Zacharias WJ, Hartman HA, et al.
In utero gene editing for monogenic lung disease.
Sci Transl Med. 2019;11:eaav8375. doi: 10.1126/
scitranslmed.aav8375.
24） Hayashi SI, Morishita R, Aoki M, et al. In
vivo transfer of gene and oligodeoxynucleotides
into skin of fetal rats by incubation in amniotic
fluid. Gene Ther. 1996;3:878-885.
25） Truzzi E, Nascimento TL, Iannuccelli V, et
al. In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with
a Mannose-Based Surfactant: A Promising Tool
for Pulmonary Tuberculosis Treatment? Nanomaterials (Basel). 2020;10:568. doi: 10.3390/
nano10030568.
26） Nishijima K, Shukunami K, Yoshinari H, et
al. Interactions among pulmonary surfactant, vernix caseosa, and intestinal enterocytes: intra-amniotic administration of fluorescently liposomes
to pregnant rabbits. Am J Physiol Lung Cell
Mol Physiol. 2012;303:L208-214. doi: 10.1152/
ajplung.00081.2011.
27） Samaridou E, Heyes J, Lutwyche P. Lipid
nanoparticles for nucleic acid delivery: Current
perspectives. Adv Drug Deliv Rev. 2020;154155:37-63. doi: 10.1016/j.addr.2020.06.002.
...
論文の公開元へ
